Table 5.
Comparison of patients with Vancouver type B2 PFF (Means ± SD)
| Group I (TXA) | Group II (No‐TXA) | P‐value | |
|---|---|---|---|
| Cases (n) | 32 | 21 | ‐ |
| Age (years) | 73.5 ± 9.8 | 70.0 ± 15.2 | 0.312* |
| Gender (male/female) | 15/17 | 11/10 | 0.695† |
| BMI (kg/m2) | 21.7 ± 3.6 | 22.0 ± 2.3 | 0.777* |
| Surgical time (min) | 139.2 ± 19.6 | 145.0 ± 24.1 | 0.343* |
| Estimated intraoperative blood loss (mL) | 386.3 ± 230.6 | 914.3 ± 493.2 | ˂0.001‡ |
| Visible blood loss (mL) | 582.8 ± 348.5 | 1718.1 ± 654.4 | ˂0.001‡ |
| Hidden blood loss (mL) | 698.7 ± 579.4 | 1400.3 ± 1121.4 | 0.037‡ |
| Allogeneic blood transfusion rate | 56.3% | 76.2% | 0.139† |
| Allogeneic blood transfusion volume (mL) | 409.4 ± 502.8 | 1281.0 ± 1177.4 | 0.005‡ |
| Symptomatic VTE (cases/incidence) | 1 (3.1%) | 2 (9.5%) | 0.705† |
*
Student's t test
†
Pearson's chi‐squared test
‡
Mann–Whitney U test.
BMI, body mass index; PFF, periprosthetic femur fractures; TXA, tranexamic acid; VTE, venous thromboembolism.